ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses
- PMID: 15193400
- DOI: 10.1016/j.vaccine.2003.12.031
ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses
Abstract
ISCOMATRIX adjuvant is capable of inducing broad and potent humoral and cellular immune responses. The components are well defined and the manufacturing process is simple and robust. Many vaccines containing the ISCOMATRIX adjuvant have been tested in a range of animal models, including human and non-human primates. Strong antibody and T cell responses have been induced in these studies. The antibody response is often achieved with lesser amounts of antigen than other adjuvant systems and the maximal responses have also been reached more quickly. Both CD4+ and CD8+ T cell responses are induced with the cytotoxic T lymphocyte responses being very long lived. Additionally, ISCOMATRIX adjuvant can be used in vaccines for induction of mucosal immune responses. This review provides an overview of the immune responses that can be elicited using ISCOMATRIX vaccines and the current state of knowledge regarding the mechanism of action of this adjuvant.
Similar articles
-
ISCOMATRIX adjuvant for antigen delivery.Adv Drug Deliv Rev. 2005 Jan 10;57(3):465-74. doi: 10.1016/j.addr.2004.09.006. Adv Drug Deliv Rev. 2005. PMID: 15560952 Review.
-
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.
-
Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.Vaccine. 2005 Apr 8;23(20):2591-601. doi: 10.1016/j.vaccine.2004.11.034. Vaccine. 2005. PMID: 15780441 Clinical Trial.
-
ISCOMs and ISCOMATRIX.Vaccine. 2009 Jul 16;27(33):4388-401. doi: 10.1016/j.vaccine.2009.05.032. Epub 2009 May 28. Vaccine. 2009. PMID: 19450632 Review.
-
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.Expert Rev Vaccines. 2007 Oct;6(5):761-72. doi: 10.1586/14760584.6.5.761. Expert Rev Vaccines. 2007. PMID: 17931156 Review.
Cited by
-
Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients.J Virol. 2008 Sep;82(18):9283-7. doi: 10.1128/JVI.01047-08. Epub 2008 Jul 9. J Virol. 2008. PMID: 18614638 Free PMC article.
-
Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.Nat Commun. 2016 Nov 7;7:13324. doi: 10.1038/ncomms13324. Nat Commun. 2016. PMID: 27819292 Free PMC article.
-
Mucosal and systemic immunization against tuberculosis by ISCOMATRIX nano adjuvant co-administered with alginate coated chitosan nanoparticles.Iran J Basic Med Sci. 2023;26(10):1162-1167. doi: 10.22038/IJBMS.2023.67564.14806. Iran J Basic Med Sci. 2023. PMID: 37736514 Free PMC article.
-
Efficacy of a non-updated, Matrix-C-based equine influenza subunit-tetanus vaccine following Florida sublineage clade 2 challenge.Vet Rec. 2014 Jun 21;174(25):633. doi: 10.1136/vr.101993. Epub 2014 May 2. Vet Rec. 2014. PMID: 24795071 Free PMC article. Clinical Trial.
-
Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Proc Natl Acad Sci U S A. 2015. PMID: 25681373 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials